Emma D. Wrenn

Emma D. Wrenn

Auto-generated profile, based on publicly available information

Emma D. Wrenn

Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EWEmma D. Wrenn
Emma D. Wrenn
AAApril A. Apfelbaum
April A. Apfelbaum
ERErin R. Rudzinski
Erin R. Rudzinski
XDXuemei Deng
Xuemei Deng
WJWei Jiang
Wei Jiang
ELElizabeth R Lawlor
Elizabeth R Lawlor
Purpose: Despite limited genetic and histologic heterogeneity, Ewing sarcoma (EwS) tumor cells are transcriptionally heterogeneous and display varying degrees of mesenchymal lineage specification in vitro. In this study, we investigated if and how transcriptional heterogeneity of EwS cells contributes to heterogeneity of tumor phenotypes in vivo. Experimental Design: Single-cell proteogenomic-sequencing of EwS cell lines was performed and integrated with patient tumor transcriptomic data. Cell subpopulations were isolated by FACS for assessment of gene expression and phenotype. Digital spatial profiling and human whole transcriptome analysis interrogated transcriptomic heterogeneity in EwS xenografts. Tumor cell subpopulations and matrix protein deposition were evaluated in xenografts and patient tumors using multiplex immunofluorescence staining. Results: We identified CD73 as a biomarker of highly mesenchymal EwS cell subpopulations in tumor models and patient biopsies. CD73+ tumor cells displayed distinct transcriptional and phenotypic properties, including selective upregulation of genes that are repressed by EWS::FLI1, and increased migratory potential. CD73+ cells were distinguished in vitro and in vivo by increased expression of matrisomal genes and abundant deposition of extracellular matrix (ECM) proteins. In epithelial-derived malignancies, ECM is largely deposited by cancer-associated fibroblasts (CAF), and we thus labeled CD73+ EwS cells, CAF-like tumor cells. Marked heterogeneity of CD73+ EwS cell frequency and distribution was detected in tumors in situ, and CAF-like tumor cells and associated ECM were observed in peri-necrotic regions and invasive foci. Conclusions: EwS tumor cells can adopt CAF-like properties, and these distinct cell subpopulations contribute to tumor heterogeneity by remodeling the tumor microenvironment. See related commentary by Kuo and Amatruda, p. 5002

2 June 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AAApril A. Apfelbaum
April A. Apfelbaum
FWFeinan Wu
Feinan Wu
AHAllegra G. Hawkins
Allegra G. Hawkins
BMBrian Magnuson
Brian Magnuson
JJJennifer A. Jiménez
Jennifer A. Jiménez
ELElizabeth R Lawlor
Elizabeth R Lawlor
Purpose: Propagation of Ewing sarcoma requires precise regulation of EWS::FLI1 transcriptional activity. Determining the mechanisms of fusion regulation will advance our understanding of tumor progression. Here we investigated whether HOXD13, a developmental transcription factor that promotes Ewing sarcoma metastatic phenotypes, influences EWS::FLI1 transcriptional activity. Experimental Design: Existing tumor and cell line datasets were used to define EWS::FLI1 binding sites and transcriptional targets. Chromatin immunoprecipitation and CRISPR interference were employed to identify enhancers. CUT&RUN and RNA sequencing defined binding sites and transcriptional targets of HOXD13. Transcriptional states were investigated using bulk and single-cell transcriptomic data from cell lines, patient-derived xenografts, and patient tumors. Mesenchymal phenotypes were assessed by gene set enrichment, flow cytometry, and migration assays. Results: We found that EWS::FLI1 creates a de novo GGAA microsatellite enhancer in a developmentally conserved regulatory region of the HOXD locus. Knockdown of HOXD13 led to widespread changes in expression of developmental gene programs and EWS::FLI1 targets. HOXD13 binding was enriched at established EWS::FLI1 binding sites where it influenced expression of EWS::FLI1-activated genes. More strikingly, HOXD13 bound and activated EWS::FLI1-repressed genes, leading to adoption of mesenchymal and migratory cell states that are normally suppressed by the fusion. Single-cell analysis confirmed that direct transcriptional antagonism between HOXD13-mediated gene activation and EWS::FLI1-dependent gene repression defines the state of Ewing sarcoma cells along a mesenchymal axis. Conclusions: Ewing sarcoma tumors are comprised of tumor cells that exist along a mesenchymal transcriptional continuum. The identity of cells along this continuum is, in large part, determined by the competing activities of EWS::FLI1 and HOXD13. See related commentary by Weiss and Bailey, p. 4360

12 June 2025 in bioRxiv
Verified
Preprint
Open access
EWEmma D. Wrenn
Emma D. Wrenn
JHJacob C. Harris
Jacob C. Harris
AAApril A. Apfelbaum
April A. Apfelbaum
JVJonah R. Valenti
Jonah R. Valenti
PLPatricia A. Lipson
Patricia A. Lipson
ELElizabeth R Lawlor
Elizabeth R Lawlor
Sub-populations of cancer-associated fibroblast (CAF)-like tumor cells deposit extracellular matrix (ECM) proteins that support Ewing sarcoma (EwS) progression and metastasis. We previously showed a hallmark of CAF-like EwS cells is their hybrid transcriptional state wherein the driver fusion oncogene, EWS::FLI1, maintains activation of proliferative programs but loses capacity to repress mesenchymal genes. Here, we studied primary patient tumors and cell line models to identify molecular drivers of this hybrid state. Our data reveal that hybrid EwS cells are induced and maintained by a TGFβ signaling positive feedback loop. Hybrid cells de-repress TGFBR2 and upregulate expression and secretion of TGFβ2 to sustain pathway activation and ECM deposition. While TGFβ ligands can potently induce growth arrest in cells of epithelial origin, we show that TGFβ1 and TGFβ2 promote cell invasion of EwS cells without affecting proliferation. Thus, stroma and tumor-derived TGFβ ligands induce and maintain hybrid EwS cells to promote pro-metastatic cell phenotypes.

13 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EWEmma D. Wrenn
Emma D. Wrenn
AAApril A. Apfelbaum
April A. Apfelbaum
ERErin R. Rudzinski
Erin R. Rudzinski
XDXuemei Deng
Xuemei Deng
WJWei Jiang
Wei Jiang
ELElizabeth R Lawlor
Elizabeth R Lawlor
Tumor heterogeneity is a major driver of cancer progression. In epithelial-derived malignancies, carcinoma-associated fibroblasts (CAFs) contribute to tumor heterogeneity by depositing extracellular matrix (ECM) proteins that dynamically remodel the tumor microenvironment (TME). Ewing sarcomas (EwS) are histologically monomorphous, mesenchyme-derived tumors that are devoid of CAFs. Here we identify a previously uncharacterized subpopulation of transcriptionally distinct EwS tumor cells that deposit pro-tumorigenic ECM. Single cell analyses revealed that these CAF-like cells differ from bulk EwS cells by their upregulation of a matrisome-rich gene signature that is normally repressed by EWS::FLI1, the oncogenic fusion transcription factor that underlies EwS pathogenesis. Further, our studies showed that ECM-depositing tumor cells express the cell surface marker CD73, allowing for their isolation ex vivo and detection in situ. Spatial profiling of tumor xenografts and patient biopsies demonstrated that CD73 + EwS cells and tumor cell-derived ECM are prevalent along tumor borders and invasive fronts. Importantly, despite loss of EWS::FLI1-mediated gene repression, CD73 + EwS cells retain expression of EWS::FLI1 and the fusion-activated gene signature, as well as tumorigenic and proliferative capacities. Thus, EwS tumor cells can be reprogrammed to adopt CAF-like properties and these transcriptionally and phenotypically distinct cell subpopulations contribute to tumor heterogeneity by remodeling the TME.

23 January 2026 in Science Advances
Verified
Journal Article
Open access
EWEmma D. Wrenn
Emma D. Wrenn
JHJacob C. Harris
Jacob C. Harris
AAApril A. Apfelbaum
April A. Apfelbaum
JVJonah R. Valenti
Jonah R. Valenti
PLPatricia A. Lipson
Patricia A. Lipson
ELElizabeth R Lawlor
Elizabeth R Lawlor
Subpopulations of cancer-associated fibroblast (CAF)–like tumor cells deposit extracellular matrix (ECM) proteins that support Ewing sarcoma (EwS) progression and metastasis. We previously showed a hallmark of CAF-like EwS cells is their hybrid transcriptional state wherein the driver fusion oncogene, EWS::FLI1, maintains activation of proliferative programs but loses capacity to repress mesenchymal genes. Here, we studied primary patient tumors and cell line models to identify molecular drivers of this hybrid state. Our data reveal that hybrid EwS cells are induced and maintained by a transforming growth factor–β (TGFβ) signaling positive feedback loop. Hybrid cells derepress TGFBR2 and up-regulate expression and secretion of TGFβ2 to sustain pathway activation and ECM deposition. Although TGFβ ligands can potently induce growth arrest in cells of epithelial origin, we show that TGFβ1 and TGFβ2 promote cell invasion of EwS cells without affecting proliferation. Thus, stroma-derived and tumor-derived TGFβ ligands induce and maintain hybrid EwS cells to promote pro-metastatic cell phenotypes.

1 December 2018 in Developmental Cell
Verified
Journal Article
Closed access
EWEmma D. Wrenn
Emma D. Wrenn
KCKevin J. Cheung
Kevin J. Cheung